PIM
PBE icon

Penobscot Investment Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Penobscot Investment Management’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.54M Hold
19,450
– – 0.12% 141
2025
Q4 		$1.6M Hold
19,450
– – 0.12% 139
2025
Q3 		$1.36M Hold
19,450
– – 0.1% 148
2025
Q2 		$1.25M Hold
19,450
– – 0.11% 154
2025
Q1 		$1.23M Hold
19,450
– – 0.12% 147
2024
Q4 		$1.29M Buy
19,450
+450
+2% +$31K 0.12% 143
2024
Q3 		$1.39M Sell
19,000
-900
-5% -$62.3K 0.12% 144
2024
Q2 		$1.29M Buy
19,900
+8,000
+67% +$507K 0.12% 141
2024
Q1 		$770K Buy
11,900
+750
+7% +$48.8K 0.08% 170
2023
Q4 		$734K Buy
11,150
+1,300
+13% +$75.6K 0.09% 169
2023
Q3 		$562K Buy
+9,850
New +$601K 0.08% 172

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
YIA
YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Penobscot Investment Management's PBE Position: Q1 2026 in Review

Penobscot Investment Management held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q1 2026 at 19,450 shares worth $1.54M. The position accounts for 0.12% of the portfolio, ranked #141.

Penobscot Investment Management first reported a position in PBE in Q3 2023 and has held it in 11 quarters since. The position peaked at $1.6M in Q4 2025. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.

  • Penobscot Investment Management held 19,450 shares of Invesco Biotechnology & Genome ETF worth $1.54M as of Q1 2026.
  • Penobscot Investment Management left its Invesco Biotechnology & Genome ETF share count unchanged in Q1 2026.
  • Invesco Biotechnology & Genome ETF made up 0.12% of Penobscot Investment Management's portfolio in Q1 2026, its #141 holding.
  • Penobscot Investment Management first reported a position in Invesco Biotechnology & Genome ETF in Q3 2023 and has held it in 11 quarters since.
  • Penobscot Investment Management's Invesco Biotechnology & Genome ETF position peaked at $1.6M in Q4 2025.
  • 100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.

Based on Penobscot Investment Management's 13F filing for Q1 2026, filed 29 Apr 2026.